文献速递产科

腹横肌平面阻滞联合低剂量舒芬太尼与高剂量舒芬太尼用于剖宫产术后镇痛:双盲研究

Transverse abdominal plane block with low-dose sufentanil vs high-dose sufentanil for postcesarean pain: a double-blind study.
PubMed 文献 · Am J Obstet Gynecol MFM · 2025-10-25

该双盲随机对照试验纳入ASA II级、足月单胎剖宫产产妇,比较腹横肌平面阻滞后PCIA含低剂量舒芬太尼(50 mcg/100 mL)与高剂量舒芬太尼(100 mcg/100 mL)的术后镇痛效果。低剂量组48小时舒芬太尼用量更少、首次按压镇痛泵更晚、按压次数更少,首次排气和下床时间更早,皮肤瘙痒、恶心呕吐和3个月慢性疼痛更少,静息和运动VAS评分更低,血清催乳素更高,初乳时间更早。

要点

  • 腹横肌平面阻滞联合低剂量舒芬太尼PCIA可减少剖宫产术后48小时舒芬太尼用量和镇痛泵按压次数。
  • 低剂量组术后首次排气和下床时间更早,皮肤瘙痒、恶心呕吐及3个月慢性疼痛更少。
  • 低剂量组术后血清催乳素更高,初乳时间更早,提示可能促进泌乳。

核心结论

  • 腹横肌平面阻滞联合低剂量舒芬太尼多模式镇痛可有效管理剖宫产术后疼痛,减少不良反应并促进产妇恢复。

研究设计与样本

  • 双盲随机对照试验,采用随机数字表法分组,纳入年龄20-40岁、身高152-175 cm、体重60-80 kg、BMI<30 kg/m2、ASA II级、足月单胎妊娠37-42周的剖宫产产妇;低剂量组(E组)n=99,高剂量组(C组)n=98。

主要发现

  • E组48小时内舒芬太尼用量少于C组(P<.001),首次按压镇痛泵时间晚于C组(P<.001),按压次数少于C组(P<.001)。
  • E组首次排气时间和首次下床时间均早于C组(均P<.001)。
  • E组皮肤瘙痒(P<.001)、恶心呕吐(P=.037)和3个月慢性疼痛(P=.011)均少于C组。
  • C组在6 h和12 h的静息及运动状态VAS值变化均高于E组(均P<.05)。
  • E组术后血清催乳素高于C组(P<.05),且首次下床时间(P<.05)和初乳时间均早于C组。

关键数值与推荐

  • E组PCIA泵含舒芬太尼50 mcg/100 mL,C组含100 mcg/100 mL,均行双侧腹横肌平面阻滞。
  • 证据等级为I级,技术效能阶段为1。

临床怎么用

  • 剖宫产术后可采用腹横肌平面阻滞联合含低剂量舒芬太尼(50 mcg/100 mL)的PCIA进行多模式镇痛。
  • 该方案可减少阿片类药物用量及相关不良反应,并可能促进产妇恢复和泌乳。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Management of postoperative pain is the main requirement of anesthesia for cesarean section. Generally, opioids (especially morphine) with transverse abdominal muscle plane block anesthesia are used as an effective analgesic method for postcesarean section pain but opioids have adverse effects of sedation, vomiting, and/or respiratory depressions of women. OBJECTIVES: To compare 2 postoperative analgesia methods (transverse abdominal plane block followed by patient-controlled intravenous analgesia (PCIA) containing a low dose of sufentanil versus PCIA containing a high dose of sufentanil) on the postoperative maternal and neonatal course after cesarean-section. STUDY DESIGN: Parturients age 20 to 40 years, height 152 to 175 cm, weight 60 to 80 kg, body mass index less than 30 kg/m2, American Society of Anesthesiologists (ASA) II grade, singleton term pregnancy, and 37 to 42 weeks of pregnancy were included in double-blind, randomized (the random number chart method) trial. Parturient underwent bilateral transverse abdominal muscle plane block anesthesia with multimodal analgesia pump containing 50 mcg/100 mL of sufentanil (Group E, n=99) or 100 mcg/100 mL of sufentanil (Group C, n=98) after cesarean section. RESULTS: Consumption of sufentanil within 48 hours in the group E was less than the group C (P<.001). The first time of postcesarean analgesic pump was later in the group E (P<.001). The number of analgesic pump compression in the group E was less than that in the group C (P<.001). The first exhaust time and first getting out of bed time in the group E were earlier than those in the group C (P<.001 for both). Postcesarean adverse reactions such as skin itching (P<.001), nausea and vomiting (P=.037), and 3 months of chronic pain (P=.011) reported fewer in the group E than those of women of the group C. The changes of the VAS value of the resting state and the movement conditions at 6 h and 12 h were higher in the group C as compared to those of group E (P<.05 for all). The serum prolactin (PRL) after cesarean section was higher in the group E compared to those of the group C (P<.05) and the first time of getting out of bed (P<.05) and colostrum's time after cesarean section were earlier in the group E. CONCLUSIONS: Transverse abdominal muscle plane block combine with sparing opioid regimen in multimode analgesia after cesarean section, provides effective management of postcesarean pain management, improve the impact of postcesarean pain on PRL secretion with, promoted maternal recovery, and with less adverse effects. LEVEL OF EVIDENCE: I. TECHNICAL EFFICACY STAGE: 1.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Guo Y, Zheng J, Wang J, et al. Transverse abdominal plane block with low-dose sufentanil vs high-dose sufentanil for postcesarean pain: a double-blind study. Am J Obstet Gynecol MFM. 2025. PMID: 41326260. doi:10.1016/j.ajogmf.2025.101823

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。